Antibiotic type | Resistance gene | Genotype (%) |
Phenotype resistance rate (%) | Consistency rate (%) | |
---|---|---|---|---|---|
Number of bacteria | Positive rate | ||||
11/15 | 73.33 | 91.66 | |||
Macrolides | 10/15 | 66.67 | 80.00 | 83.33 | |
5/15 | 33.33 | 41.66 | |||
Lincosamides | 9/15 | 60.00 | 66.67 | 89.99 | |
7/15 | 46.67 | 100.00 | |||
6/15 | 40.00 | 85.71 | |||
Tetracyclines | 6/15 | 40.00 | 46.67 | 85.71 | |
5/15 | 33.33 | 71.42 |
Virulence gene profile | Distributiona (%) |
---|---|
3 (20) | |
2 (13.33) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) | |
1 (6.67) |
Antimicrobial drug class | Resistance gene | Primer sequence (5′–3′) | Annealing temperature (°C) | PCR product size (bp) | Reference |
---|---|---|---|---|---|
F: GGTGGCTGGGGGGTAGATGTATTAACTGG | |||||
Lincosamides | R: GCTCTCTTTGAAATACATGGTATTTTTCGATC | 56 | 323 | ( |
|
F: AACTTAGGCATTCTGGCTCAC | |||||
R: TCCCACTGTTCCATATCGTCA | 50 | 515 | ( |
||
F: TCGATAGGAACAGCAGTA | |||||
R: CAGCAGATCCTACTCCTT | 44 | 169 | ( |
||
Tetracyclines | |||||
F: GTGGACAAAGGTACAACGAG | 50 | 406 | |||
R: CGGTAAAGTTCGTCACACAC | |||||
( |
|||||
F: CATAGACAAGCCGTTGACC | |||||
R: ATGTTTTTGGAACGCCAGAG | 48 | 667 | |||
F: CGAGTGAAAAAGTACTCAACC | 48 | 652 | |||
R: AGTAACGGTACTTAAATTGTTTAC | |||||
F: ATCTTTGAAATCGGCTCAGG | |||||
Macrolides | R: CAAACCCGTATTCCACGATT | 47 | 295 | ( |
|
F: GTTCAAGAACAATCAATACAGAG | |||||
R: GGATCAGGAAAAGGACATTTTAC | 48 | 421 |
Isolate no. | MIC (μg/mL) |
||||||||
---|---|---|---|---|---|---|---|---|---|
PEN | A/C | AMP | CET | OXA | SMZ | SXT | TE | DOX | |
SH07 | ≤0.125 (S3) | 1/0.5 (R) | ≤0.125 (S) | 32 (R) | 1 (S) | 4 (S) | 0.5/9.5 (S) | 4 (S) | 4 (S) |
SH07-2 | 4 (R) | ≤0.25/0.12 (S) | ≤0.125 (S) | 0.5 (S) | 16 (R) | 256 (I) | 0.25/4.8 (S) | 16 (R) | 2 (S) |
SH12 | ≤0.125 (S) | ≤0.25/0.12 (S) | 0.25 (I) | 0.5 (S) | 4 (R) | 8 (S) | 0.5/9.5 (S) | 32 (R) | 4 (S) |
SH33 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 0.5 (S) | 16 (R) | 64 (S) | 0.5/9.5 (S) | 32 (R) | 0.5 (S) |
SH45 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 1 (S) | 32 (R) | 64 (S) | 0.25/4.8 (S) | 64 (R) | 2 (S) |
HLJ008 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 32 (R) | 32 (R) | 128 (S) | 0.25/4.8 (S) | 32 (R) | 2 (S) |
HLJ048-2 | 2 (R) | ≤0.25/0.12 (S) | ≤0.125 (S) | 1 (S) | 4 (R) | 2 (S) | 0.5/9.5 (S) | 16 (R) | 8 (I) |
HLJ030-3 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 0.5 (S) | 0.5 (S) | 64 (S) | 0.5/9.5 (S) | 64 (R) | 4 (S) |
NM025 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 1 (S) | 1 (S) | 64 (S) | 0.25/4.8 (S) | 32 (R) | 16 (R) |
HB016 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 0.25 (S) | 16 (R) | 128 (S) | 0.5/9.5 (S) | 16 (R) | 4 (S) |
NM-2-72-4 | 8 (R) | ≤0.25/0.12 (S) | 2 (R) | 1 (S) | 16 (R) | 128 (S) | 0.25/4.8 (S) | 32 (R) | 32 (R) |
NM-2-034-3 | 8 (R) | 16/8 (R) | 4 (R) | 0.5 (S) | 4 (R) | 64 (S) | 2/38 (I) | 4 (S) | 4 (S) |
SH-2-46-1 | ≤0.125 (S) | ≤0.25/0.12 (S) | ≤0.125 (S) | 0.5 (S) | 32 (R) | 128 (S) | 0.25/4.8 (S) | 16 (R) | 4 (S) |
SH-2-14-2 | 2 (R) | 4/2 (R) | ≤0.125 (S) | 1 (S) | 16 (R) | 128 (S) | 0.25/4.8 (S) | 32 (R) | 8 (I) |
SD-2-009-2 | ≤0.125 (S) | 16/8 (R) | ≤0.125 (S) | 0.5 (S) | 4 (R) | 128 (S) | 0.25/4.8 (S) | 8 (I) | 4 (S) |
Drug resistance rate (%) (/15) | |||||||||
S | 66.67 (10) | 73.33 (11) | 80.00 (12) | 86.67 (13) | 20.00 (3) | 93.33 (14) | 93.33 (14) | 13.33 (2) | 73.33 (11) |
I | 0 (0) | 0 (0) | 6.67 (1) | 0 (0) | 0 (0) | 6.67 (1) | 6.67 (1) | 6.67 (1) | 13.33 (2) |
R | 33.33 (5) | 26.67 (4) | 13.33 (2) | 13.33 (2) | 80.00 (12) | 0 (0) | 0 (0) | 80.00 (12) | 13.33 (2) |
Virulence gene | Penicillin | Cefoxitin | Oxacillin | Doxycycline | Gentamicin | Clindamycin | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B | Exp(B) | P | B | Exp(B) | P | B | Exp(B) | P | B | Exp(B) | P | B | Exp(B) | P | B | Exp(B) | P | |
40.537 | 4.028 | 0.999 | 1.099 | 3.000 | 1.000 | −42.406 | 0.000 | 0.999 | 1.099 | 3.000 | 1.000 | −41.307 | 0.000 | 0.999 | −61.799 | 0.000 | 0.999 | |
−20.269 | 0.000 | 1.000 | −60.718 | 0.000 | 0.999 | 62.916 | 2.108 | 0.999 | 19.699 | 3.590 | 1.000 | 62.105 | 9.369 | 0.999 | −62.493 | 0.000 | 0.999 | |
0.000 | 1.000 | 1.000 | −19.411 | 0.000 | 0.999 | −21.896 | 0.000 | 0.999 | −19.411 | 0.000 | 0.999 | −19.411 | 0.000 | 0.999 | −0.693 | 0.500 | 0.744 | |
−0.934 | 0.393 | 1.000 | 42.406 | 2.610 | 0.999 | −84.812 | 0.000 | 0.999 | −38.011 | 0.000 | 1.000 | −80.417 | 0.000 | 0.999 | −81.880 | 0.000 | 0.999 | |
42.406 | 2.610 | 0.999 | −40.209 | 0.000 | 0.999 | 42.406 | 2.610 | 0.999 | 40.209 | 2.900 | 0.999 | 40.209 | 2.900 | 0.999 | 0.000 | 1.000 | 1.000 | |
21.203 | 1.615 | 1.000 | −19.411 | 0.000 | 1.000 | −21.896 | 0.000 | 1.000 | −19.411 | 0.000 | 1.000 | −19.411 | 0.000 | 1.000 | −42.412 | 0.000 | 0.999 | |
−41.472 | 0.000 | 1.000 | −1.099 | 0.333 | 1.000 | 42.406 | 2.610 | 1.000 | −1.099 | 0.333 | 1.000 | 41.307 | 8.699 | 1.000 | −20.080 | 0.000 | 1.000 | |
0.000 | 1.000 | 1.000 | −1.099 | 0.333 | 1.000 | 42.406 | 2.610 | 0.999 | −1.099 | 0.333 | 1.000 | −1.099 | 0.333 | 1.000 | 21.203 | 1.615 | 1.000 |
Drug category | Antibacterial drugs |
---|---|
penicillin | |
ampicillin | |
β-lactams | amoxicillin / clavulanic acid |
oxacillin | |
cefoxitin | |
Macrolides | erythromycin |
Lincosamides | clindamycin |
Aminoglycosides | gentamicin |
Tetracyclines | doxycycline tetracycline |
Chloramphenicols | florfenicol |
Ansamycins | rifampicin |
Glycopeptides | vancomycin |
Quinolones | ciprofloxacin |
Sulfonamides | sulfisoxazole |
sulfamethoxazole |
Isolate no. | Drug resistance pattern | Resistant gene | Virulence gene |
---|---|---|---|
SH07 | (A/C)/CET/ERY | ||
SH07-2 | PEN/OXA/TE/ERY/CLI/FFC | ||
SH12 | OXA/TE/ERY/CLI/GM | ||
SH33 | OXA/TE/ERY/CLI/GM | ||
SH45 | OXA/TE/ERY/CLI | ||
HLJ008 | CET/OXA/TE/ERY/CLI | ||
HLJ030-3 | TE/CLI/FFC | ||
NM025 | TE/DOX/ERY | ||
HB016 | OXA/TE/ERY/CLI/GM | ||
SH-2-46-1 | OXA/TE/ERY |
Virulence factor | Virulence gene | Primer sequence (5′–3′) | Annealing temperature (°C) | PCR size product (bp) |
---|---|---|---|---|
F: CATTGCGTAGTCACCTCCC | ||||
β-haemolysin/cytolysis | R: GGGTTTCCACAGTTGCTTGA | 54 | 399 | |
F: TAACAGTTATGATACTTCACAGAC ⎕ | ||||
αC protein | R: ACGACTTTCTTCCGTCCACTTAGG | 51 | 535 | |
F: CCAAGACTTCAGCCACAAGG | ||||
C5a peptidase | R: CAATTCCAGCCAATAGCAGC | 57 | 591 | |
F: ACCGTCTGAAATGATGTGG | ||||
Laminin binding protein | R: GATTGACGTTGTCTTCTGC | 51 | 572 | |
Glutamine synthetase | F: ACGTATGAACAGAGTTGGCTATAA | 52 | 471 | |
R: TCCTCTGATAATTGCATTCCAC | ||||
CAMP factor | F: ATGGGATTTGGGATAACTAAGCTAG | 52 | 193 | |
R: AGCGTGTATTCCAGATTTCCTTAT | ||||
Hyaluronidase | F: ACAAATGGAACGACGTGACTAT | 52 | 346 | |
R: CACCAATTGGCAGAGCCT | ||||
F: AAGCAACTAGAAGAGGAAGC | ||||
βC protein | R: TTCTGCTCTGGTGTTTTAGG | 53 | 479 | |
Bacterial immunogenic | F: AACCAGAAGCCAAGCCAGCAACC | 58 | 127 | |
adhesive | R: AGTGGACTTGCGGCTTCACCC | |||
F: CGGGATTGATCTAAGTCGCT | ||||
Invasion-associated gene | R: CCATCAACATCAGTCGCTAA | 53 | 459 | |
F: AGAGCCAAGTAGGTCAACTTATAG | ||||
Fibrin binding protein B | R: TTCATTGCGTCTCAAACCG | 54 | 290 |
Isolate no. | MIC (μg/mL) |
||||||
---|---|---|---|---|---|---|---|
ERY | CLI | GM | CIP | FFC | RIF | VAN | |
SH07 | 16 (R) | 0.25 (S) | 4 (S) | 0.5 (S) | 2 (S) | 0.5 (S) | 0.5 (S) |
SH07-2 | 16 (R) | 4 (R) | 4 (S) | 0.5 (S) | 16 (R) | 0.125 (S) | 0.5 (S) |
SH12 | 32 (R) | 8 (R) | 16 (R) | 0.5 (S) | 4 (S) | 0.5 (S) | 0.5 (S) |
SH33 | 16 (R) | 8 (R) | 16 (R) | 0.5 (S) | 8 (I) | 0.5 (S) | 0.5 (S) |
SH45 | 64 (R) | 8 (R) | 2 (S) | 2 (I) | 8 (I) | 0.5 (S) | 0.5 (S) |
HLJ008 | 16 (R) | 4 (R) | 4 (S) | 0.5 (S) | 4 (S) | 0.5 (S) | 0.5 (S) |
HLJ048-2 | 16 (R) | 16 (R) | 8 (I) | 0.5 (S) | 4 (S) | 1 (S) | 0.5 (S) |
HLJ030-3 | 0.5 (S) | 16 (R) | 2 (S) | 0.5 (S) | 16 (R) | 0.5 (S) | 0.5 (S) |
NM025 | 16 (R) | 0.5 (S) | 1 (S) | 0.5 (S) | 8 (I) | 0.5 (S) | 0.5 (S) |
HB016 | 16 (R) | 4 (R) | 16 (R) | 0.5 (S) | 4 (S) | 0.5 (S) | 0.5 (S) |
NM-2-72-4 | 2 (I) | 0.5 (S) | 32 (R) | 0.5 (S) | 16 (R) | 0.5 (S) | 0.5 (S) |
NM-2-034-3 | 0.5 (S) | 16 (R) | 4 (S) | 4 (R) | 16 (R) | 0.5 (S) | 0.5 (S) |
SH-2-46-1 | 16 (R) | 0.5 (S) | 4 (S) | 0.5 (S) | 4 (S) | 0.5 (S) | 0.5 (S) |
SH-2-14-2 | 16 (R) | 16 (R) | 4 (S) | 4 (R) | 8 (I) | 0.5 (S) | 0.5 (S) |
SD-2-009-2 | 32 (R) | 0.5 (S) | 16 (R) | 4 (R) | 16 (R) | 0.5 (S) | 0.5 (S) |
Drug resistance rate (%) (/15) | |||||||
S | 13.33 (2) | 33.33 (5) | 60.00 (9) | 73.33 (11) | 40.00 (6) | 100 (15) | 100 (15) |
I | 6.67 (1) | 0 (0) | 6.67 (1) | 6.67 (1) | 26.67 (4) | 0 (0) | 0 (0) |
R | 80.00 (12) | 66.67 (10) | 33.33 (5) | 20.00 (3) | 33.33 (5) | 0 (0) | 0 (0) |